News for Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the best penny stocks under $1 to buy now. On June 25, Ovid Therapeutics announced a definitive agreement with Immedica Pharma AB. Under this agreement, Ovid will sell its future royalty rights related to sales of ganaxolone outside of China for $7 million in cash. In 2024, Ovid […]

NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. ( OVID), a biopharmaceutical company dedicated to developing small molecule medicines for b

Ovid Therapeutics (OVID) to participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. The company focuses on small molecule medicine

A significant event for investors in OVID is set for July 22, when a meeting will take place in New York, hosted by B. Riley. This gathering is expected to prov

Analysts at H.C. Wainwright have adjusted their price target for Ovid Therapeutics (OVID), reducing it from $2 to $1.50. Despite this revision, they maintain a

**media[570620]**

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 18.75% and 45.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to t

**media[563181]**

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. ( OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. ( OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions

Madison Avenue Partners, LP (Trades, Portfolio), a prominent investment firm, recently executed a significant transaction involving Ovid Therapeutics Inc. On De

Oppenheimer has upgraded Ovid Therapeutics (OVID) to outperform from perform, citing its drug candidate OV329. Read more here.

Two preclinical studies to be presented on OV329, a potential next-generation GABA aminotransferase inhibitor, highlighting its safety profile and lack of ocula

Analysis-RFK Jr vow to purge FDA sets up collision with Big Pharma

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of -5.26% and 15.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Marinus reports positive phase 3 seizure treatment trial results

Marinus Pharmaceuticals' patent upheld by PTAB

Ovid stock gets boost from promising OV329 toxicity profile - B.Riley